Experimental drug ALMB-0166 tested in spinal cord injury patients

NCT ID NCT05524103

Completed Disease control Sponsor: AlaMab Therapeutics (Shanghai) Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a single dose of an experimental drug called ALMB-0166 in 24 people with acute spinal cord injury. The main goal was to check safety and how the drug moves through the body. Participants had moderate to severe injuries and were scheduled for surgery within 72 hours. Results will help decide if further studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALMB-0166 (an experimental drug given as a single injection)
What this could lead to: If this drug is safe and shows promise, it could point toward a treatment that helps limit damage after a spinal cord injury.
What could go wrong: This is a very early phase 1 trial with only 24 participants, focused on safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE SPINAL CORD INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

spinal cord injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE SPINAL CORD INJURY

Contacts and locations

Locations

Peking University Third Hospital

Beijing, Beijing Municipality, China
Peking University Third Hospital Medical Science Research Ethic Committee

Beijing, Beijing Municipality, 100191, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.